Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy By Ogkologos - June 16, 2025 587 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Julia Louis-Dreyfus Talks About The Side Effects of Chemotherapy May 3, 2019 Moving target – retrotransposable elements and cancer July 11, 2023 Building a Support Community During Cancer: “Your Stories” Podcast December 14, 2021 ESMO Sarcoma and Rare Cancers Congress 2024 March 5, 2024 Load more HOT NEWS Divarasib in Combination with Cetuximab Demonstrates a Manageable Safety Profile and... CVS, Walgreens, Rite Aid Suspend Sales Of Zantac Following Cancer-Causing Concerns Consensus on Conceptual Framework for Precision Cancer Medicine in Germany Improving Care for Underserved People With Cancer and Evaluating Delays in...
